PROFILE |
 |
APBiotech helps scientists and drugmakers blaze a new trail in biotechnology. The firm, a joint venture of Amersham (formerly Nycomed Amersham, which owns 55%) and Pharmacia (45%), makes equipment and supplies for biotechnology, drug development, and gene sequencing research. Its products include MegaBACE automated DNA sequencers; chromatographic systems to purify insulin, vaccines, and proteins; protein-labeling systems; and microassays. As biotechnology expands, so does the firm; it joined The SNP Consortium to map DNA variations that create individuality. With IPOs in a slump, Amersham has put on hold plans to list 10% of its stake in APBiotech on the Nasdaq.
COMPETITION |
 |
Agilent Technologies, Inc. (A)
Applera Corporation (dossier)
Bio-Rad Laboratories, Inc. (BIO)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
1999 Sales (mil.): 864.10
1-Yr. Sales Growth: 18.5%
Employees: 4,200
Revenue per employee: $205,738.10
KEY PEOPLE |
 |
Andrew Carr
CEO
Sandra Cartie
CFO
CONTACT INFO |
 |
SE-751 84
Uppsala, Sweden
Phone: 46-18 -0 00
Fax: 46-18 -2 00
Online: Web Site
|